{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:52:59Z","timestamp":1788447179757,"version":"build-2803163510"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T00:00:00Z","timestamp":1460592000000},"content-version":"vor","delay-in-days":135,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ihj.2015.10.380","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T04:22:53Z","timestamp":1448425373000},"page":"S13-S34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S2","title":["The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants"],"prefix":"10.1016","volume":"67","author":[{"given":"Jamshed","family":"Dalal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Bhave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Oomman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Vora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiman","family":"Kahali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fali","family":"Poncha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Gambhir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydip Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakul","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumitra","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.S.","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvro","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upendra","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2015.10.380_bib0580","doi-asserted-by":"crossref","first-page":"e257","DOI":"10.1161\/circ.114.4.257","volume":"114","author":"Fuster","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0585","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib0590","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-5273(98)00125-9","article-title":"Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham Atrial Fibrillation Project","volume":"65","author":"Lip Lip","year":"1998","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0595","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"key":"10.1016\/j.ihj.2015.10.380_bib0600","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation: the Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib0605","first-page":"e269","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0610","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0615","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0620","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0167-5273(98)00125-9","article-title":"Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham Atrial Fibrillation Project","volume":"65","author":"Lip","year":"1998","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0625","first-page":"505","article-title":"Epidemiology and risk factor for AF in India","volume":"3","author":"Deore","year":"2013","journal-title":"J Prev Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0630","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ihj.2012.07.014","article-title":"Atrial fibrillation in a tertiary care institute \u2013 a prospective study","volume":"64","author":"Bhardwaj","year":"2012","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0635","doi-asserted-by":"crossref","first-page":"14","DOI":"10.15420\/usc.2007.4.1.14","article-title":"Epidemiology and economic burden of atrial fibrillation","volume":"4","author":"Bajpai","year":"2007","journal-title":"US Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0640","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Stroke Risk in Atrial Fibrillation Working Group.","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ihj.2015.10.380_bib0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-116-1-1","article-title":"Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk","volume":"116","author":"The Stroke Prevention in Atrial Fibrillation Investigators","year":"1992","journal-title":"Ann Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.ihj.2015.10.380_bib0650","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1159\/000069936","article-title":"Long-term outcome after ischaemic stroke\/transient ischaemic attack","volume":"16","author":"Hankey","year":"2003","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.ihj.2015.10.380_bib0655","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2015.10.380_bib0660","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0665","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1160\/TH09-11-0757","article-title":"The CHADS2 score for stroke risk stratification in atrial fibrillation\u2014friend or foe?","volume":"104","author":"Karthikeyan","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib0670","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1160\/TH11-02-0061","article-title":"Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis","volume":"106","author":"Keogh","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib0675","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.112.102319","article-title":"Net clinical benefit of warfarin: extending the reach of antithrombotic therapy for atrial fibrillation","volume":"125","author":"Fuster","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0680","doi-asserted-by":"crossref","first-page":"257","DOI":"10.5551\/jat.7153","article-title":"Recent progress in antithrombotic therapy for atrial fibrillation","volume":"18","author":"Velu","year":"2011","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ihj.2015.10.380_bib0685","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","article-title":"Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?","volume":"34","author":"Lip","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0690","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ihj.2015.10.380_bib0695","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \u2018real world\u2019 patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib0700","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH11-12-0827","article-title":"The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER)","volume":"108","author":"Omran","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib0705","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/clc.22294","article-title":"Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2-VASc, R2 CHADS2, HAS-BLED, ATRIA, and more)","volume":"37","author":"Dzeshka","year":"2014","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0710","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1186\/1471-2458-14-776","article-title":"Risk factors of stroke in Western and Asian countries: a systematic review and meta-analysis of prospective cohort studies","volume":"14","author":"Chen","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ihj.2015.10.380_bib0715","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(09)70340-0","article-title":"Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis","volume":"9","author":"van Asch","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0720","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.ijcard.2012.10.052","article-title":"Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated Chinese patients with atrial fibrillation","volume":"168","author":"Guo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0725","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1161\/01.CIR.0000063575.17904.4E","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"107","author":"Hirsh","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0730","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0735","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2015.10.380_bib0740","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-120-11-199406010-00001","article-title":"Risk factors for intracranial hemorrhage in outpatients taking warfarin","volume":"120","author":"Hylek","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0745","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and -LY trials","volume":"38","author":"Amin","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.ihj.2015.10.380_bib0750","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1378\/chest.126.6.1938","article-title":"Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta analysis","volume":"126","author":"Reynolds","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.ihj.2015.10.380_bib0755","doi-asserted-by":"crossref","first-page":"600","DOI":"10.5694\/j.1326-5377.2000.tb124127.x","article-title":"Consensus guidelines for warfarin therapy. Recommendations from the Australasian Society of Thrombosis and Haemostasis","volume":"172","author":"Gallus","year":"2000","journal-title":"Med J Aust"},{"key":"10.1016\/j.ihj.2015.10.380_bib0760","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib0765","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1477-9560-12-5","article-title":"Warfarin and atrial fibrillation: from ideal to real the warfarin affaire","volume":"12","author":"Molteni","year":"2014","journal-title":"Thromb J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0770","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archinte.165.10.1095","article-title":"Systematic overview of warfarin and its drug and food interactions","volume":"165","author":"Holbrook","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0775","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.amjopharm.2012.09.006","article-title":"Warfarin-antibiotic interactions in older adults of an outpatient anticoagulation clinic","volume":"10","author":"Ghaswalla","year":"2012","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.ihj.2015.10.380_bib0780","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.ihj.2015.10.380_bib0785","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1358\/dof.2005.030.09.938760","article-title":"Dabigatran\/dabigatran etexilate","volume":"30","author":"Sorbera","year":"2005","journal-title":"Drugs Fut"},{"key":"10.1016\/j.ihj.2015.10.380_bib0790","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/0091270005274550","article-title":"Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement","volume":"45","author":"Stangier","year":"2005","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0795","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40262-012-0030-9","article-title":"New oral anticoagulants: comparative pharmacology with vitamin K antagonists","volume":"52","author":"Scaglione","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ihj.2015.10.380_bib0800","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0805","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0810","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1474-4422(10)70274-X","article-title":"Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial","volume":"9","author":"Diener","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0815","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0820","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib0825","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","author":"Lauffenburger","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ihj.2015.10.380_bib0830","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.amjmed.2014.01.031","article-title":"Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0835","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.amjmed.2013.12.005","article-title":"Myocardial ischemic events in \u2018real world\u2019 patients with atrial fibrillation treated with dabigatran or warfarin","volume":"127","author":"Larsen","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0840","doi-asserted-by":"crossref","first-page":"h1857","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","author":"Abraham","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.ihj.2015.10.380_bib0845","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrd3185","article-title":"The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"10","author":"Perzborn","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ihj.2015.10.380_bib0850","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ihj.2015.10.380_bib0855","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 \u2013 an oral, direct Factor Xa inhibitor \u2013 after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0860","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0865","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0870","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/eurheartj\/ehr342","article-title":"Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment","volume":"32","author":"Fox","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0875","doi-asserted-by":"crossref","first-page":"A148","DOI":"10.1161\/str.43.suppl_1.A148","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular AF in the ROCKET-AF trial","volume":"43","author":"Halperin","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib0880","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1185\/03007995.2014.907140","article-title":"Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients","volume":"30","author":"Lalibert\u00e9","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ihj.2015.10.380_bib0885","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0890","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0895","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/eurheartj\/ehu181","article-title":"Edoxaban: a focused review of its clinical pharmacology","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0900","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0905","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7326\/0003-4819-157-10-201211200-00532","article-title":"Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review","volume":"157","author":"Adam","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0910","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2015.10.380_bib0915","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.ijcard.2012.03.148","article-title":"Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients","volume":"167","author":"Capodanno","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0920","first-page":"640","article-title":"Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups","author":"G\u00f3mez-Outes","year":"2013","journal-title":"Thrombosis"},{"key":"10.1016\/j.ihj.2015.10.380_bib0925","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/STROKEAHA.113.000883","article-title":"Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and metaanalysis","volume":"44","author":"Albertsen","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib0930","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijcard.2012.09.187","article-title":"Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact?","volume":"168","author":"Guo","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0935","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1474-4422(12)70092-3","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial","volume":"11","author":"Easton","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0940","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib0945","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","article-title":"Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation","volume":"50","author":"Shen","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib0950","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0955","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3109\/07853890.2014.952327","article-title":"Anticoagulant-related gastrointestinal bleeding \u2013 could this facilitate early detection of benign or malignant gastrointestinal lesions?","volume":"46","author":"Clemens","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib0960","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/jgs.12799","article-title":"New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials","volume":"62","author":"Sardar","year":"2014","journal-title":"J Am Geriatr Soc"},{"issue":"suppl 2","key":"10.1016\/j.ihj.2015.10.380_bib0965","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","article-title":"Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban","volume":"40","author":"St\u00f6llberger","year":"2015","journal-title":"Herz"},{"key":"10.1016\/j.ihj.2015.10.380_bib0970","series-title":"Prescribing information","author":"PRADAXA\u00ae (dabigatran etexilate mesylate)","year":"2013"},{"key":"10.1016\/j.ihj.2015.10.380_bib0975","series-title":"Prescribing information December","author":"ELIQUIS (apixaban) tablets","year":"2012"},{"key":"10.1016\/j.ihj.2015.10.380_bib0980","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ihj.2015.10.380_bib0985","first-page":"305","article-title":"A review of warfarin dosing and monitoring","volume":"14","author":"Gurk-Turner","year":"2001","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.ihj.2015.10.380_bib0990","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib0995","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.ihj.2015.10.380_bib1000","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate \u2013 a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib1005","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/bjh.12975","article-title":"Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology","volume":"166","author":"Kitchen","year":"2014","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.ihj.2015.10.380_bib1010","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jth.12227","article-title":"The role of the laboratory in treatment with new oral anticoagulants","volume":"11","author":"Baglin","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib1015","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.thromres.2012.09.004","article-title":"Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature","volume":"130","author":"Douxfils","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.ihj.2015.10.380_bib1020","first-page":"A11395","article-title":"Small molecule antidote for anticoagulants [abstract]","volume":"126","author":"Laulicht","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib1025","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib1030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib1035","series-title":"55th ASH annual meeting, New Orleans (abstract) [ONLINE]","article-title":"A phase 2 randomized, double blindplacebo controlled trial demonstrating reversal of rivaroxaban-induced anticoagulationin healthy subjects by andexanet alpha (PRT064445), an antidote forfactor Xa inhibitors","author":"Crowther","year":"2013"},{"issue":"suppl 137","key":"10.1016\/j.ihj.2015.10.380_bib1040","article-title":"Sustained reversal of apixaban anticoagulation with andexanet alpha using a bolus plus infusion regimen in a phase II placebo controlled trial","volume":"35","author":"Crowther","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib1045","series-title":"ASH; Abstract 4269","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulationin healthy subjects by andexanet alfa (PRT064445), a Universal Antidotefor Factor Xa (fXa) Inhibitors","author":"Crowther","year":"2014"},{"key":"10.1016\/j.ihj.2015.10.380_bib1050","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ihj.2015.10.380_bib1055","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib1060","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib1065","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tmrv.2006.08.002","article-title":"Anticoagulants and their reversal","volume":"21","author":"Schulman","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.ihj.2015.10.380_bib1070","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0147-9563(99)70031-2","article-title":"Allergy to protamine sulfate","volume":"28","author":"Porsche","year":"1999","journal-title":"Heart Lung"},{"key":"10.1016\/j.ihj.2015.10.380_bib1075","doi-asserted-by":"crossref","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ihj.2015.10.380_bib1080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17300","article-title":"Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review","volume":"17","author":"Lane","year":"2013","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.ihj.2015.10.380_bib1085","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/europace\/euu008","article-title":"Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey","volume":"16","author":"Potpara","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ihj.2015.10.380_bib1090","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib1095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2015.10.380_bib1100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2015.10.380_bib1105","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib1110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2015.10.380_bib1115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib1120","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2015.10.380_bib1125","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1161\/STROKEAHA.109.192535","article-title":"Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association\/American Stroke Association","volume":"40","author":"del Zoppo","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib1130","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/STROKEAHA.107.181486","volume":"38","author":"Adams","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.ihj.2015.10.380_bib1135","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1001\/jama.2012.6756","article-title":"Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator","volume":"307","author":"Xian","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.ihj.2015.10.380_bib1140","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2015.10.380_bib1145","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1212\/WNL.0000000000000145","article-title":"Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"82","author":"Culebras","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ihj.2015.10.380_bib1150","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrcardio.2014.22","article-title":"Oral anticoagulants for Asian patients with atrial fibrillation","volume":"11","author":"Sabir","year":"2014","journal-title":"Nat Rev Cardiol"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483215008251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483215008251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:22:50Z","timestamp":1762176170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483215008251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":115,"alternative-id":["S0019483215008251"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2015.10.380","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2015.10.380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier, a division of Reed Elsevier India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}